1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Innoviva, Inc.
  6. News
  7. Summary
    INVA   US45781M1018

INNOVIVA, INC.

(INVA)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
15.46 USD   +0.39%
05/24INNOVIVA : TENDER AND SUPPORT AGREEMENT - Form 8-K
PU
05/24INNOVIVA, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innoviva : To Buy Back GlaxoSmithKline's Stake For $392 Million

05/20/2021 | 10:16am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC -1.17% 1733.2 Delayed Quote.7.88%
INNOVIVA, INC. 0.39% 15.46 Delayed Quote.-10.38%
All news about INNOVIVA, INC.
05/24INNOVIVA : TENDER AND SUPPORT AGREEMENT - Form 8-K
PU
05/24INNOVIVA, INC. : Entry into a Material Definitive Agreement, Other Events, Financial State..
AQ
05/23Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash..
MT
05/23Innoviva to Acquire Entasis Therapeutics
BU
05/23Innoviva to Acquire Entasis Therapeutics
AQ
05/05INNOVIVA, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/04INNOVIVA, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
05/02INNOVIVA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
04/29INNOVIVA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
04/28Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Busine..
AQ
More news
Analyst Recommendations on INNOVIVA, INC.
More recommendations
Financials (USD)
Sales 2022 397 M - -
Net income 2022 - - -
Net cash 2022 249 M - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 1 078 M 1 078 M -
EV / Sales 2022 2,09x
EV / Sales 2023 1,91x
Nbr of Employees 5
Free-Float 68,0%
Chart INNOVIVA, INC.
Duration : Period :
Innoviva, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNOVIVA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 15,46 $
Average target price 20,50 $
Spread / Average Target 32,6%
Managers and Directors
Pavel Raifeld Chief Executive Officer
George W. Bickerstaff Chairman
Jules Haimovitz Independent Director
Sarah J. Schlesinger Independent Director
Mark A. Dipaolo Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INNOVIVA, INC.-10.38%1 078
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098